ArticleTherapeutic advances in medical oncology2024

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.

Aditya Bardia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.